Endogenous tissue plasminogen activator enhances fibrinolysis and limits thrombus formation in a clinical model of thrombosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 5, 2013, Pages 1105-1111

  Lucking, Andrew J ^a   Gibson, Kyle R ^a   Paterson, Elspeth E ^a   Faratian, Dana ^a   Ludlam, Christopher A ^a   Boon, Nicholas A ^a   Fox, Keith A A ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

endogenous fibrinolysis; endothelial function; endothelium; thrombosis; tissue plasminogen activator

Indexed keywords

ALTEPLASE; BRADYKININ; D DIMER; ENALAPRIL; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOTTING; CORONARY ARTERY THROMBOSIS; ENZYME RELEASE; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84876285090     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300395     Document Type: Article

References (33)

1. Rosenberg RD, Aird WC. Vascular-bed-specifc hemostasis and hyperco-agulable states. N Engl J Med. 1999;340:1555-1564.
2. van den Eijnden-Schrauwen Y, Kooistra T, de Vries RE, Emeis JJ. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood. 1995;85:3510-3517.
3. Tranquille N, Emeis JJ. Protein synthesis inhibition by cycloheximide does not affect the acute release of tissue-type plasminogen activator. Thromb Haemost. 1989;61:442-447.
4. Fox KA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, Bergmann SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation. 1985;72:1346-1354.
5. Jern S, Selin L, Bergbrant A, Jern C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemost. 1994;72:588-594.
6. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fbrinolytic capacity of the endo-thelium. Thromb Haemost. 1997;78:1242-1248.
7. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001;103:1936-1941.
8. Gudmundsdóttir IJ, Megson IL, Kell JS, Ludlam CA, Fox KA, Webb DJ, Newby DE. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans. Circulation. 2006;114:1625-1632.
9. Newby DE, Witherow FN, Wright RA, Bloomfeld P, Ludlam CA, Boon NA, Fox KA, Webb DJ. Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fbrinolytic capacity in vivo. Heart. 2002;87:48-53.
10. Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol. 2003;23:695-701.
11. Labinjoh C, Newby DE, Dawson P, Johnston NR, Ludlam CA, Boon NA, Webb DJ. Fibrinolytic actions of intra-arterial angiotensin II and bradyki-nin in vivo in man. Cardiovasc Res. 2000;47:707-714.
12. Robinson SD, Ludlam CA, Boon NA, Newby DE. Endothelial fbri-nolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2007;27:1651-1656.
13. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood. 1996;88:1525-1541.
14. Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Infuence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis. 1986;6:312-320.
15. Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular fow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafuoroethylene. J Lab Clin Med. 1987;110:706-718.
16. Lev EI, Patel R, Karim A, Kleiman A, Badimon JJ, Kleiman NS. Anti-thrombotic effect of bivalirudin compared with eptifbatide and unfrac-tionated heparin in diabetic patients: an ex vivo human study. Thromb Haemost. 2006;95:441-446.
17. Wåhlander K, Eriksson-Lepkowska M, Nyström P, Eriksson UG, Sarich TC, Badimon JJ, Kalies I, Elg M, Bylock A. Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thromb Haemost. 2006;95:447-453.
18. Zafar MU, Farkouh ME, Osende J, Shimbo D, Palencia S, Crook J, Leadley R, Fuster V, Chesebro JH. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost. 2007;97:487-492.
19. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo fow chamber. Thromb Haemost. 2007;98:883-888.
20. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2001;38:1402-1408.
21. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bra-dykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol. 2002;40:961-966.
22. Hrafnkelsdóttir T, Ottosson P, Gudnason T, Samuelsson O, Jern S. Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension. 2004;44:300-304.
23. Hrafnkelsdóttir T, Wall U, Jern C, Jern S. Impaired capacity for endogenous fbrinolysis in essential hypertension. Lancet. 1998;352:1597-1598.
24. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cycloox-ygenase-independent pathway. Circulation. 2000;102:2190-2196.
25. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999;33:1431-1435.
26. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic signifcance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
27. Chowienczyk PJ, Cockcroft JR, Ritter JM. Differential inhibition by NG-monomethyl-L-arginine of vasodilator effects of acetylcho-line and methacholine in human forearm vasculature. Br J Pharmacol. 1993;110:736-738.
28. Genser N, Lechleitner P, Maier J, Dienstl F, Artner-Dworzak E, Puschendorf B, Mair J. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin Chem. 1998;44:209-214.
29. Koster RW, Cohen AF, Kluft C, Kasper FJ, van der Wouw PA, Weatherley BC. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. Clin Pharmacol Ther. 1991;50:267-277.
30. Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol (Lond). 1989;412:543-555.
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
32. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fbrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation. 1999;99:1411-1415.
33. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, Kinoshita M. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001;37:1565-1570.